{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:21:41Z","timestamp":1788387701944,"version":"build-2803163510"},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the impact of one\u2010third\u2010dose (1\/3D) bacillus Calmette\u2010Gu\u00e9rin (BCG) on oncological outcomes in a large cohort of patients with non\u2010muscle\u2010invasive bladder cancer (NMIBC) treated with adequate BCG (as defined by the US Food &amp; Drug Administration (FDA)) in a real\u2010world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We performed an institutional review board\u2010approved review of patients with NMIBC treated with adequate BCG at our institution between 2000 and 2020. Patients were stratified according to whether they had received 1\/3D BCG or full\u2010dose (FD) BCG. Time to recurrence, time to progression and cancer\u2010specific survival were estimated using Kaplan\u2013Meier methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 563 patients with NMIBC treated with adequate BCG, 150 (26.6%) received 1\/3D and 413 (73.4%) received FD. The use of 1\/3D BCG did not adversely affect time to recurrence (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.449) or time to progression (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.716), and this remained consistent when patients were stratified by individual 2021 European Association of Urology (EAU) prognostic factor risk groups. Cancer\u2010specific survival was similar in patients receiving 1\/3D and those receiving FD BCG (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.320).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The use of 1\/3D BCG was not associated with adverse oncological outcomes in a large cohort of patients receiving adequate BCG for intermediate\u2010 and high\u2010risk NMIBC. Based on this real\u2010world experience, risk\u2010stratified split\u2010vial dosing may represent a valuable approach for other institutions facing BCG shortages whilst also providing reassurance to patients who may be concerned about suboptimal outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.15661","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T18:12:11Z","timestamp":1638295931000},"page":"323-330","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Reduced\u2010dose bacillus Calmette\u2010Gu\u00e9rin (BCG) in an era of BCG shortage: real\u2010world experience from a tertiary cancer centre"],"prefix":"10.1111","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-8399","authenticated-orcid":false,"given":"Niyati","family":"Lobo","sequence":"first","affiliation":[{"name":"Department of Urology University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K.","family":"Bree","sequence":"additional","affiliation":[{"name":"Department of Urology University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8098-901X","authenticated-orcid":false,"given":"Patrick J.","family":"Hensley","sequence":"additional","affiliation":[{"name":"Department of Urology University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela M.","family":"Nogueras\u2010Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Biostatistics University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanth","family":"Abraham","sequence":"additional","affiliation":[{"name":"Department of Urology University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neema","family":"Navai","sequence":"additional","affiliation":[{"name":"Department of Urology University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin P.","family":"Dinney","sequence":"additional","affiliation":[{"name":"Department of Urology University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[{"name":"Department of Urology University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64043-8"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2003.04655.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.12.014"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.04.038"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64273-5"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2003.11.049"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.08.010"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-179018"},{"key":"e_1_2_7_11_1","unstructured":"Sanofi Pasteur.Sanofi Pasteur statement on discontinuation of BCG. Available at:https:\/\/www.news.sanofi.us\/press\u2010statements?item=1002. Accessed September 2021"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.11.031"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.039"},{"key":"e_1_2_7_14_1","volume-title":"BCG\u2010Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment Guidance for Industry","author":"US Food and Drug Administration","year":"2018"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.4070"},{"key":"e_1_2_7_16_1","unstructured":"BabjukM BurgerM Comp\u00e9ratEet al. EAU guidelines on non\u2010muscle\u2010invasive bladder cancer (TaT1 and CIS) 2021. Available at:https:\/\/uroweb.org\/guideline\/non\u2010muscle\u2010invasive\u2010bladder\u2010cancer\/. Accessed August 2021"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2002.02722.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000173919.28835.aa"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.04.002"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.04.066"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2020.08.004"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2018.07.055"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.03.004"},{"key":"e_1_2_7_25_1","unstructured":"American Urological Association.BCG shortage info. Available at:https:\/\/www.auanet.org\/about\u2010us\/bcg\u2010shortage\u2010info. Accessed September 2021"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.15661","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bju.15661","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.15661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:50:26Z","timestamp":1761738626000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.15661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1111\/bju.15661"],"URL":"https:\/\/doi.org\/10.1111\/bju.15661","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]},"assertion":[{"value":"2021-12-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}